Jessica K.R. Boult1, Mahmoud El Shemerly2, Felix Bachmann2, Laurenz Kellenberger2, Heidi Lane2, Paul McSheehy2, and Simon P. Robinson1
1The Institute of Cancer Research, Sutton, United Kingdom, 2Basilea Pharmaceutica International Ltd, Basel 4005, Switzerland
1The Institute of Cancer Research, Sutton, United Kingdom, 2Basilea Pharmaceutica International Ltd, Basel 4005, Switzerland
FGFR inhibitor
derazantinib causes dose-dependent inhibition of endothelial cell proliferation,
VEGFR signalling and vascular permeability in mouse skin, and induces a
reduction in fractional blood volume, as assessed by susceptibility-contrast
MRI, in colorectal tumour xenografts.
Figure 3. T2w images and paramagnetic maps of
baseline R2*, USPIO-induced ΔR2* and fractional blood
volume (fBV) from representative athymic nude mice pre and post 48h treatment
with vehicle, 80mg/kg DZB daily or 50mg/kg vatalanib twice daily.
Figure
4. Quantification
of baseline R2* and fractional blood volume (fBV) in all mice pre and post 48h treatment with vehicle,
80mg/kg DZB daily or 50mg/kg vatalanib twice daily. DZB and vatalanib induced
significant reductions in fBV (p<0.05, 2-way repeated measures ANOVA).
